Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer

BACKGROUND: Antibody-drug conjugate (ADC) construction poses numerous challenges that limit clinical progress. In particular, common bioconjugation methods afford minimal control over the site of drug coupling to antibodies. Here, such difficulties are overcome through re-bridging of the inter-chain...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Greene, Michelle K., Chen, Ting, Robinson, Eifion, Straubinger, Ninfa L., Minx, Charlene, Chan, Darren K. W., Wang, Jun, Burrows, James F., Van Schaeybroeck, Sandra, Baker, James R., Caddick, Stephen, Longley, Daniel B., Mager, Donald E., Straubinger, Robert M., Chudasama, Vijay, Scott, Christopher J.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7653048/
https://ncbi.nlm.nih.gov/pubmed/32913288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-01046-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados